WEBULL

Is Integra LifeSciences (IART) Undervalued After Its Recent Share Price Rebound?

Simply Wall St · 2d ago

Recent performance and setup

Integra LifeSciences Holdings (IART) has quietly climbed about 11% over the past month, even as its one year return remains down more than 40%. This creates an interesting reset for patient investors.

See our latest analysis for Integra LifeSciences Holdings.

That 11% 1 month share price return stands in sharp contrast to the roughly 42% year to date share price slide and deeply negative multi year total shareholder returns. This suggests recent gains look more like a tentative stabilisation than a full momentum shift.

If Integra’s rebound has you rethinking the broader healthcare space, this could be a good moment to compare it with other healthcare stocks that are starting to show improving trends.

Against that backdrop of modest growth, heavy losses, and a small discount to analyst targets, investors now face the key question: Is Integra genuinely undervalued, or is the market already pricing in any future recovery?

Most Popular Narrative: 15.5% Undervalued

With Integra LifeSciences Holdings last closing at $13.42 versus a narrative fair value near the mid teens, the numbers imply a meaningful upside if assumptions hold.

The company's strategic investments in portfolio expansion within regenerative technologies, international market penetration, and cost structure optimization (targeted to deliver $25–$30 million in annualized savings) aim to diversify revenue streams, accelerate top-line growth, and drive sustained margin expansion in coming years.

Read the complete narrative.

Curious how modest revenue growth, a sharp swing from deep losses to steady profits, and a re rated earnings multiple all fit together? The narrative’s valuation hinges on that mix of recovery, operating leverage, and a future profit profile that looks very different from today. Want to see exactly how those moving parts stack up into a double digit upside case?

Result: Fair Value of $15.88 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, sustained product delays or unresolved operational issues could erode market share and margins, undermining the expected recovery and potential valuation upside.

Find out about the key risks to this Integra LifeSciences Holdings narrative.

Build Your Own Integra LifeSciences Holdings Narrative

If you see Integra’s story differently or want to stress test the assumptions yourself, you can build a complete narrative in just minutes: Do it your way.

A great starting point for your Integra LifeSciences Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Ready for more high conviction ideas?

Do not stop at one opportunity. Use the Simply Wall Street Screener to pinpoint focused ideas that match your strategy before the market catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.